The financing will in part support development of the firm's PI3K inhibitor paxalisib in PIK3CA-mutated brain cancer and HER2-positive breast cancer.

This month, the firm also performed a 1-for-15 reverse share split to maintain compliance with Nasdaq listing requirements.

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.

The platform will support Anocca's Phase I/II trial of its therapies under development for treating KRAS-mutated pancreatic cancer.

BE-101 is an engineered B-cell therapy, in which a functional copy of the FIX gene is inserted into patients' own B cells in vivo.

The partners will seek CAP/CLIA certification for an organoid-based assay and conduct clinical validation studies of it as a tool to guide treatment.

NEW YORK – ARTBio this week said it has raised $132 million in Series B financing to advance its alpha radioligand therapies and bolster the supply chain underlying their development.

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

The agency previously declined to approve Atara's first Ebvallo biologics license application but has accepted a data package it resubmitted this month.